Catalent (NYSE:CTLT) Stock Rating Reaffirmed by Robert W. Baird

Robert W. Baird reiterated their neutral rating on shares of Catalent (NYSE:CTLT) in a research note published on Tuesday, Benzinga reports. Robert W. Baird currently has a $63.50 price target on the stock.

Several other equities research analysts also recently weighed in on CTLT. Barclays raised their target price on shares of Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a research note on Friday, June 28th. StockNews.com assumed coverage on shares of Catalent in a research note on Wednesday, September 18th. They issued a sell rating for the company. William Blair restated a market perform rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Royal Bank of Canada restated a sector perform rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $59.83.

Catalent Stock Performance

Shares of CTLT stock opened at $60.34 on Tuesday. The firm has a market cap of $10.92 billion, a price-to-earnings ratio of -9.89, a PEG ratio of 2.32 and a beta of 1.15. Catalent has a 52-week low of $31.80 and a 52-week high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The company’s 50 day moving average is $59.69 and its 200 day moving average is $57.33.

Catalent (NYSE:CTLT) last announced its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, sell-side analysts anticipate that Catalent will post 0.85 EPS for the current fiscal year.

Insider Transactions at Catalent

In other news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,403 shares of company stock worth $902,503. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after purchasing an additional 218,682 shares during the period. Capital World Investors increased its holdings in Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after buying an additional 1,098,474 shares in the last quarter. Cadian Capital Management LP increased its holdings in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares in the last quarter. Millennium Management LLC increased its holdings in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares in the last quarter. Finally, Capital International Investors increased its holdings in Catalent by 1.2% in the fourth quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock valued at $134,541,000 after buying an additional 34,856 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.